Like Sandman Sleep Diagnostics

closed 9/21/2009 via BusinessWire

Embla Systems, acquired Sandman Sleep Diagnostics

synopsis: Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. The Sleep Diagnostics product line includes several products sold under the Sandman(TM) brand.
buyer: Embla Systems
Embla is the leader in the global sleep diagnostic market, creating medical solutions for sleep professionals and delivering value through innovative products and service excellence. The privately held company manufactures, distributes and services its products in over 65 countries. "
target parent: Covidien
target: Sandman Sleep Diagnostics
The Sandman® sleep diagnostic systems provides sleep study professionals world-wide with a range of robust, technologically advanced products for sleep study recording and analysis in clinical, home and research applications.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/31/2012 via BNC Analysis

Alveron Energy Corp., merged with Safebrain Systems Inc.

synopsis: Alveron Energy Corp. has acquired Safebrain Systems Inc. Safebrain has developed a unique technological advancement in the field of potentially detecting concussions and head trauma in athletes. It works in two separate ways: a sensor that is mounted on the helmet of an athlete and software that allows in-depth analysis of any impact event.
buyer: Alveron Energy Corp.
Alveron Energy Corp., a development stage company, focuses on operating as a wind and hydro electric energy generation company. It has a joint venture agreement with Yantai Alveron Energy Development Company to develop a 48 megawatts wind energy plant in Shandong, China. "
target: Safebrain Systems Inc.
Safebrain has developed a technological advancement in the field of potentially detecting concussions and head trauma in athletes. It works in two separate ways: a sensor that is mounted on the helmet of an athlete and software that allows in-depth analysis of any impact event.
price ($mm)
$0.60
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/9/2019 via PE Hub

Micromed SpA, acquired OSG bvba

synopsis: Micromed, an Italian medical device company, has acquired OSG BVBA, a Belgium-based sleep diagnostics software company strongly positioned in sleep neuromonitoring and clinical neurophysiology. With the acquisition, Micromed will gain direct access to the Benelux market, thanks to OSG’s strong position in the area.
buyer parent: ArchiMed
buyer: Micromed SpA
Micromed is an Italian medical device company delivering solutions in Neurophysiology worldwide. Partnering with hospitals, sleep labs, and research centers on a global scale, Micromed manufactures and markets neurodiagnostic hardware and software to neurologists, clinicians and researchers. "
target: OSG bvba
OSG is a Belgian developer of software products for Sleep Research and Brain Research. With their products BrainRT and SleeptRT, OSG is highly regarded in sleep neuromonitoring and clinical neurophysiology with advanced capabilities in AI as it relates to sleep scoring and data interpretation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2019 via Company Press Release

NEC Corp., acquired OncoImmunity

synopsis: NEC Corporation, a leader in the integration of IT and network technologies, has acquired OncoImmunity AS, a bioinformatics company dedicated to the development of software solutions that facilitate the selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies.
buyer: NEC Corp. (TSE:6701:$28,669.80)
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. "
target: OncoImmunity
Based in Norway, OncoImmunity AS is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/18/2019 via BNC Analysis

NVIDIA Corporation, acquired Parabricks

synopsis: Computational technology company Nvidia has acquired sequencing analysis software developer Parabricks. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
buyer: NVIDIA Corporation (NVDA:$19,256.00)
NVIDIA Corporation is the worldwide leader in programmable graphics processor technologies. The Company creates innovative, industry-changing products for computing, consumer electronics, and mobile devices. "
target: Parabricks
Parabricks is a sequencing analysis software developer. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/27/2016 via BNC Analysis

Venaxis, Inc., will acquire Strand Life Sciences

synopsis: Venaxis, a developer of an in vitro diagnostic test for acute appendicitis, is to acquire Strand Life Sciences, a cancer genomics firm. Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
buyer: Venaxis, Inc. (BIOP:$0.01)
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1™ Test, which is designed to aid in the identification of patients at low risk for acute appendicitis. "
target: Strand Life Sciences
Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/25/2020 via Company Press Release

Simcyp Limited, purchased Neurodegenerative Technology Assets from In Silico Biosciences, Inc.

synopsis: Certara, the global model-informed drug development and decision support leader, has acquired a range of neurodegenerative diseases modeling and simulation technology assets from In Silico Biosciences, Inc., a company that offers computer simulation support in drug development.
buyer parent: Certara
buyer: Simcyp Limited
Certara’s Simcyp division is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. "
seller: In Silico Biosciences, Inc.
The assets include a platform of multiple integrated quantitative systems pharmacology modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Wiley, purchased Informatics products from Bio-Rad Laboratories

synopsis: John Wiley and Sons Inc., a global leader in research and education, announced the acquisition of Bio-Rad Laboratories, Inc.’s Informatics products including the company’s spectroscopy software and spectral databases.
buyer: Wiley (NYSE:JW.A:$1,864.09)
Wiley drives the world forward with research and education. Through publishing, platforms and services, they help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. "
seller: Bio-Rad Laboratories (BIO:$2,311.66)
The acquisition includes the Informatics Spectroscopy Software and Spectral Databases from Bio-Rad Laboratories, a manufacturer of products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/14/2018 via BusinessWire

Illumina, Inc., acquired Edico Genome Inc.

synopsis: Illumina, Inc.  announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing. Edico Genome’s DRAGEN Bio-IT Platform uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
buyer: Illumina, Inc. (ILMN:$3,556.00)
Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. "
target: Edico Genome Inc.
Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Their vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/23/2017 via BusinessWire

Omicia, acquired Spiral Genetics

synopsis: Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform.
buyer: Omicia
Clinicians and scientists utilize Omicia’s tools to quickly process and analyze genomic data and ultimately improve patient outcomes. Headquartered in Oakland, California, Omicia was founded by renowned scientists and industry veterans who are pioneers in bioinformatics, genomics and diagnostics. "
target: Spiral Genetics
Headquartered in Seattle, WA, Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. They specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2016 via BusinessWire

PierianDx, acquired Tute Genomics

synopsis: PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced the acquisition of Tute Genomics, a genomics software company based in Provo, UT. The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs.
buyer: PierianDx
Founded in 2011, PierianDx is the leading provider of genomic software. They enable health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. "
target: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/25/2016 via Company Press Release

Vela Diagnostics Pte. Ltd., purchased Data Interpretation Division from Lifecode, Inc.

synopsis: Vela Diagnostics announced that it has acquired the data interpretation division of Lifecode Inc., a Foster City, California-based cancer molecular company. The data interpretation products and services from Lifecode will be connected to Vela Diagnostics’ Next-Generation Sequencing Sentosa® SQ Reporter Software.
buyer: Vela Diagnostics Pte. Ltd.
Vela Diagnostics is a worldwide supplier of integrated life sciences and diagnostic solutions that help provide customers with valuable molecular information. It delivers innovative technology and products* that address many of the clinical, technical and economic issues facing laboratories. "
seller: Lifecode, Inc.
Lifecode Inc’s data interpretation service provides access to Lifecode’s data integration framework, interpretation and report generation pipelines. Lifecode is a specialized CLIA certified clinical laboratory focused on the genetic basis of human disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/2/2015 via PR Newswire

Tute Genomics, acquired Knome, Inc.

synopsis: Tute Genomics, the leader in clinical sequencing infomatics, announced its acquisition of key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commericial advancements in modern human genetics.
buyer: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights. "
target: Knome, Inc.
Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/4/2015 via BusinessWire

Agilent Technologies Inc., will acquire Cartagenia

synopsis: Agilent Technologies Inc. will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs. Cartagenia provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays.
buyer: Agilent Technologies Inc. (A:$4,720.00)
Agilent Technologies Inc. is a global leader in life sciences, diagnostics and applied chemical markets. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. "
target: Cartagenia
Cartagenia helps labs to confidently interpret, report and share genomic variants. Reduce turnaround time, build informed variant assessment pipelines, generate clinical grade lab reports, and manage increasing volumes of data. Bring together CNVs and molecular variation. Use clinical phenotypes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/10/2020 via PR Web

HealthLytix merged with Cortechs Labs Inc,

synopsis: CorTechs Labs Inc., the leading quantitative neuroimaging software company, announced that it has merged with sister company HealthLytix, a healthcare technology company developing new applications in genetics and medical imaging to improve the screening and early detection of cancer and neurodegenerative diseases.
buyer: Cortechs Labs Inc
CorTechs Labs is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. "
target: HealthLytix
HealthLytix is a precision health company and developer of quantitative medical imaging solutions that leverage machine learning. HealthLytix creates data analytics solutions to provide comprehensive insights into health status based on genetics, quantitative imaging, and other medical information.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/20/2019 via Company Press Release

InVitae, will acquire Clear Genetics

synopsis: Invitae Corporation, one of the fastest growing genetic information companies in the U.S., will acquire Clear Genetics, a leading developer of software for providing genetic services at scale whose HIPAA-compliant platform offers an automated and comprehensive solution to deliver genetic services at scale.
buyer: InVitae (NVTA:$389.09)
Invitae is one of the fastest growing genetic information companies in the U.S. Invitae Corporation's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. "
target: Clear Genetics
Clear Genetics is a Y Combinator company and leader in developing innovative, patient-centric software to thoughtfully integrate genetics into routine patient care. Their HIPAA-compliant platform offers an automated and comprehensive solution to deliver genetic services at scale.
price ($mm)
$50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/23/2021 via GlobeNewswire

Dante Labs, acquired Cambridge Cancer Genomics Limited

synopsis: Dante Labs, a leading genomics and diagnostics company, has acquired UK-based Cambridge Cancer Genomics (CCG.ai), a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.
buyer: Dante Labs
Dante Labs is a global genomic platform for diagnostics and pharma, built on three pillars: its software, its genomic database, and the integration with its clinical laboratories. Dante Labs is also a global provider of COVID-19 testing solutions for governments, businesses and individuals. "
target: Cambridge Cancer Genomics Limited
UK-based Cambridge Cancer Genomics (CCG.ai) was founded to ensure that each patient has the right drug, at the right time, to beat their cancer. CCG.ai builds software that enables data-driven precision oncology and systematically develops data-driven biomarkers indicative of treatment response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/21/2009 via BusinessWire

Embla Systems, acquired Sandman Sleep Diagnostics

synopsis: Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. The Sleep Diagnostics product line includes several products sold under the Sandman(TM) brand.
buyer: Embla Systems
Embla is the leader in the global sleep diagnostic market, creating medical solutions for sleep professionals and delivering value through innovative products and service excellence. The privately held company manufactures, distributes and services its products in over 65 countries. "
target parent: Covidien
target: Sandman Sleep Diagnostics
The Sandman® sleep diagnostic systems provides sleep study professionals world-wide with a range of robust, technologically advanced products for sleep study recording and analysis in clinical, home and research applications.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/21/2009 via BusinessWire

Embla Systems, acquired Sandman Sleep Diagnostics

synopsis: Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. The Sleep Diagnostics product line includes several products sold under the Sandman(TM) brand.
buyer: Embla Systems
Embla is the leader in the global sleep diagnostic market, creating medical solutions for sleep professionals and delivering value through innovative products and service excellence. The privately held company manufactures, distributes and services its products in over 65 countries. "
target parent: Covidien
target: Sandman Sleep Diagnostics
The Sandman® sleep diagnostic systems provides sleep study professionals world-wide with a range of robust, technologically advanced products for sleep study recording and analysis in clinical, home and research applications.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/21/2009 via BusinessWire

Embla Systems, acquired Sandman Sleep Diagnostics

synopsis: Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. The Sleep Diagnostics product line includes several products sold under the Sandman(TM) brand.
buyer: Embla Systems
Embla is the leader in the global sleep diagnostic market, creating medical solutions for sleep professionals and delivering value through innovative products and service excellence. The privately held company manufactures, distributes and services its products in over 65 countries. "
target parent: Covidien
target: Sandman Sleep Diagnostics
The Sandman® sleep diagnostic systems provides sleep study professionals world-wide with a range of robust, technologically advanced products for sleep study recording and analysis in clinical, home and research applications.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/31/2012 via BNC Analysis

Alveron Energy Corp., merged with Safebrain Systems Inc.

synopsis: Alveron Energy Corp. has acquired Safebrain Systems Inc. Safebrain has developed a unique technological advancement in the field of potentially detecting concussions and head trauma in athletes. It works in two separate ways: a sensor that is mounted on the helmet of an athlete and software that allows in-depth analysis of any impact event.
buyer: Alveron Energy Corp.
Alveron Energy Corp., a development stage company, focuses on operating as a wind and hydro electric energy generation company. It has a joint venture agreement with Yantai Alveron Energy Development Company to develop a 48 megawatts wind energy plant in Shandong, China. "
target: Safebrain Systems Inc.
Safebrain has developed a technological advancement in the field of potentially detecting concussions and head trauma in athletes. It works in two separate ways: a sensor that is mounted on the helmet of an athlete and software that allows in-depth analysis of any impact event.
price ($mm)
$0.60
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/9/2019 via PE Hub

Micromed SpA, acquired OSG bvba

synopsis: Micromed, an Italian medical device company, has acquired OSG BVBA, a Belgium-based sleep diagnostics software company strongly positioned in sleep neuromonitoring and clinical neurophysiology. With the acquisition, Micromed will gain direct access to the Benelux market, thanks to OSG’s strong position in the area.
buyer parent: ArchiMed
buyer: Micromed SpA
Micromed is an Italian medical device company delivering solutions in Neurophysiology worldwide. Partnering with hospitals, sleep labs, and research centers on a global scale, Micromed manufactures and markets neurodiagnostic hardware and software to neurologists, clinicians and researchers. "
target: OSG bvba
OSG is a Belgian developer of software products for Sleep Research and Brain Research. With their products BrainRT and SleeptRT, OSG is highly regarded in sleep neuromonitoring and clinical neurophysiology with advanced capabilities in AI as it relates to sleep scoring and data interpretation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2019 via Company Press Release

NEC Corp., acquired OncoImmunity

synopsis: NEC Corporation, a leader in the integration of IT and network technologies, has acquired OncoImmunity AS, a bioinformatics company dedicated to the development of software solutions that facilitate the selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies.
buyer: NEC Corp. (TSE:6701:$28,669.80)
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. "
target: OncoImmunity
Based in Norway, OncoImmunity AS is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines and cell therapies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/18/2019 via BNC Analysis

NVIDIA Corporation, acquired Parabricks

synopsis: Computational technology company Nvidia has acquired sequencing analysis software developer Parabricks. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
buyer: NVIDIA Corporation (NVDA:$19,256.00)
NVIDIA Corporation is the worldwide leader in programmable graphics processor technologies. The Company creates innovative, industry-changing products for computing, consumer electronics, and mobile devices. "
target: Parabricks
Parabricks is a sequencing analysis software developer. Based in Ann Arbor, Michigan, Parabricks has developed technology that leans on graphics processing units to accelerate the analysis of whole genomes to less than one hour.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/27/2016 via BNC Analysis

Venaxis, Inc., will acquire Strand Life Sciences

synopsis: Venaxis, a developer of an in vitro diagnostic test for acute appendicitis, is to acquire Strand Life Sciences, a cancer genomics firm. Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
buyer: Venaxis, Inc. (BIOP:$0.01)
Venaxis is a Colorado-based in vitro diagnostic company focused on developing and commercializing its unique multi-biomarker diagnostic test, the APPY1™ Test, which is designed to aid in the identification of patients at low risk for acute appendicitis. "
target: Strand Life Sciences
Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/25/2020 via Company Press Release

Simcyp Limited, purchased Neurodegenerative Technology Assets from In Silico Biosciences, Inc.

synopsis: Certara, the global model-informed drug development and decision support leader, has acquired a range of neurodegenerative diseases modeling and simulation technology assets from In Silico Biosciences, Inc., a company that offers computer simulation support in drug development.
buyer parent: Certara
buyer: Simcyp Limited
Certara’s Simcyp division is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. "
seller: In Silico Biosciences, Inc.
The assets include a platform of multiple integrated quantitative systems pharmacology modules of brain physiology and pathology specifically developed for the study of neurodegenerative conditions, including Alzheimer’s, Parkinson’s and Huntington’s disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Wiley, purchased Informatics products from Bio-Rad Laboratories

synopsis: John Wiley and Sons Inc., a global leader in research and education, announced the acquisition of Bio-Rad Laboratories, Inc.’s Informatics products including the company’s spectroscopy software and spectral databases.
buyer: Wiley (NYSE:JW.A:$1,864.09)
Wiley drives the world forward with research and education. Through publishing, platforms and services, they help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. "
seller: Bio-Rad Laboratories (BIO:$2,311.66)
The acquisition includes the Informatics Spectroscopy Software and Spectral Databases from Bio-Rad Laboratories, a manufacturer of products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/14/2018 via BusinessWire

Illumina, Inc., acquired Edico Genome Inc.

synopsis: Illumina, Inc.  announced that it acquired Edico Genome, the leading provider of data analysis acceleration solutions for next-generation sequencing. Edico Genome’s DRAGEN Bio-IT Platform uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
buyer: Illumina, Inc. (ILMN:$3,556.00)
Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. "
target: Edico Genome Inc.
Based in San Diego and founded in 2013, Edico Genome Inc. develops cutting edge solutions that power the genomic revolution. Their vision is to revolutionize genome sequencing analysis by providing unprecedented speed, scale and accuracy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/23/2017 via BusinessWire

Omicia, acquired Spiral Genetics

synopsis: Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform.
buyer: Omicia
Clinicians and scientists utilize Omicia’s tools to quickly process and analyze genomic data and ultimately improve patient outcomes. Headquartered in Oakland, California, Omicia was founded by renowned scientists and industry veterans who are pioneers in bioinformatics, genomics and diagnostics. "
target: Spiral Genetics
Headquartered in Seattle, WA, Spiral Genetics is a bioinformatics company that develops high performance software for analyzing next-generation sequencing data. They specialize in large-scale DNA data analysis for medical, pharmaceutical and agricultural research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2016 via BusinessWire

PierianDx, acquired Tute Genomics

synopsis: PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced the acquisition of Tute Genomics, a genomics software company based in Provo, UT. The acquisition furthers PierianDx’s goal to be the most comprehensive, integrated platform to enable personalized medicine for clinical labs.
buyer: PierianDx
Founded in 2011, PierianDx is the leading provider of genomic software. They enable health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. "
target: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/25/2016 via Company Press Release

Vela Diagnostics Pte. Ltd., purchased Data Interpretation Division from Lifecode, Inc.

synopsis: Vela Diagnostics announced that it has acquired the data interpretation division of Lifecode Inc., a Foster City, California-based cancer molecular company. The data interpretation products and services from Lifecode will be connected to Vela Diagnostics’ Next-Generation Sequencing Sentosa® SQ Reporter Software.
buyer: Vela Diagnostics Pte. Ltd.
Vela Diagnostics is a worldwide supplier of integrated life sciences and diagnostic solutions that help provide customers with valuable molecular information. It delivers innovative technology and products* that address many of the clinical, technical and economic issues facing laboratories. "
seller: Lifecode, Inc.
Lifecode Inc’s data interpretation service provides access to Lifecode’s data integration framework, interpretation and report generation pipelines. Lifecode is a specialized CLIA certified clinical laboratory focused on the genetic basis of human disease.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/2/2015 via PR Newswire

Tute Genomics, acquired Knome, Inc.

synopsis: Tute Genomics, the leader in clinical sequencing infomatics, announced its acquisition of key assets of Knome, a renowned human-genome interpretation company whose systems and services helped spearhead several of the greatest commericial advancements in modern human genetics.
buyer: Tute Genomics
Tute Genomics provides a cloud-based genome informatics solution to help diagnostic labs and health systems process next-generation sequencing data in a secure fashion. Tute is powering the world's genomic knowledge through enterprise informatics, genome interpretation, and clinical insights. "
target: Knome, Inc.
Knome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/4/2015 via BusinessWire

Agilent Technologies Inc., will acquire Cartagenia

synopsis: Agilent Technologies Inc. will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs. Cartagenia provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays.
buyer: Agilent Technologies Inc. (A:$4,720.00)
Agilent Technologies Inc. is a global leader in life sciences, diagnostics and applied chemical markets. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. "
target: Cartagenia
Cartagenia helps labs to confidently interpret, report and share genomic variants. Reduce turnaround time, build informed variant assessment pipelines, generate clinical grade lab reports, and manage increasing volumes of data. Bring together CNVs and molecular variation. Use clinical phenotypes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/10/2020 via PR Web

HealthLytix merged with Cortechs Labs Inc,

synopsis: CorTechs Labs Inc., the leading quantitative neuroimaging software company, announced that it has merged with sister company HealthLytix, a healthcare technology company developing new applications in genetics and medical imaging to improve the screening and early detection of cancer and neurodegenerative diseases.
buyer: Cortechs Labs Inc
CorTechs Labs is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. "
target: HealthLytix
HealthLytix is a precision health company and developer of quantitative medical imaging solutions that leverage machine learning. HealthLytix creates data analytics solutions to provide comprehensive insights into health status based on genetics, quantitative imaging, and other medical information.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/20/2019 via Company Press Release

InVitae, will acquire Clear Genetics

synopsis: Invitae Corporation, one of the fastest growing genetic information companies in the U.S., will acquire Clear Genetics, a leading developer of software for providing genetic services at scale whose HIPAA-compliant platform offers an automated and comprehensive solution to deliver genetic services at scale.
buyer: InVitae (NVTA:$389.09)
Invitae is one of the fastest growing genetic information companies in the U.S. Invitae Corporation's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. "
target: Clear Genetics
Clear Genetics is a Y Combinator company and leader in developing innovative, patient-centric software to thoughtfully integrate genetics into routine patient care. Their HIPAA-compliant platform offers an automated and comprehensive solution to deliver genetic services at scale.
price ($mm)
$50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/23/2021 via GlobeNewswire

Dante Labs, acquired Cambridge Cancer Genomics Limited

synopsis: Dante Labs, a leading genomics and diagnostics company, has acquired UK-based Cambridge Cancer Genomics (CCG.ai), a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.
buyer: Dante Labs
Dante Labs is a global genomic platform for diagnostics and pharma, built on three pillars: its software, its genomic database, and the integration with its clinical laboratories. Dante Labs is also a global provider of COVID-19 testing solutions for governments, businesses and individuals. "
target: Cambridge Cancer Genomics Limited
UK-based Cambridge Cancer Genomics (CCG.ai) was founded to ensure that each patient has the right drug, at the right time, to beat their cancer. CCG.ai builds software that enables data-driven precision oncology and systematically develops data-driven biomarkers indicative of treatment response.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Sandman Sleep Diagnostics


read more

Sandman Sleep Diagnostics

Safebrain Systems Inc.

OSG bvba

OncoImmunity

Parabricks

Strand Life Sciences

In Silico Biosciences, Inc.

Bio-Rad Laboratories

Edico Genome Inc.

Spiral Genetics

Tute Genomics

Lifecode, Inc.

Knome, Inc.

Cartagenia

HealthLytix

Clear Genetics

Cambridge Cancer Genomics Limited

read more

Sandman Sleep Diagnostics

read more

Sandman Sleep Diagnostics

read more

Sandman Sleep Diagnostics

Safebrain Systems Inc.

OSG bvba

OncoImmunity

Parabricks

Strand Life Sciences

In Silico Biosciences, Inc.

Bio-Rad Laboratories

Edico Genome Inc.

Spiral Genetics

Tute Genomics

Lifecode, Inc.

Knome, Inc.

Cartagenia

HealthLytix

Clear Genetics

Cambridge Cancer Genomics Limited

Geography
Matching Companies